Over the course of his 23 years at Axinn, Mike Keeley has obtained antitrust clearance for large and complex strategic mergers, tried monopolization and patent jury cases, arbitrated international commercial disputes and, most importantly, developed relationships with some of the best companies in the world. Clients value Mike's business-oriented approach to transactions and commercial disputes and his ability and willingness to give quick and clear guidance. A substantial part of Mike's work involves the intersection of antitrust and intellectual property.
Mike's recent antitrust work on strategic transactions includes Tyson Foods’ $1.2 billion sale of its pet treats business to General Mills; Dell Technologies’ $4 billion sale of Boomi to TPG and Francisco Partners; Tyler Technologies’ $2.3 billion acquisition of NIC Inc.; Tyson Foods’ acquisition of American Proteins; Tyson Foods acquisition of Keystone Foods from Marfrig; Tyson Foods’ acquisition of Smart Chicken; Dell’s $67 billion acquisition of EMC; Interactive Data Corporation’s $5 billion acquisition by Intercontinental Exchange Inc.; Thermo Fisher Scientific's $13.6 billion acquisition of Life Technologies; SunGard in its $9 billion sale to Fidelity National; Tyler Technologies in its acquisition of New World Systems; A&P in its acquisition of Pathmark Stores; Take-Two Interactive Software in Electronic Arts' hostile bid for Take-Two; GameStop's acquisition of Electronics Boutique; Harcourt, Inc.'s acquisition by Reed Elsevier and Thomson.
Where mergers have been challenged, Mike has tried and prevailed in multiple cases, including: the Antitrust Division's challenge to SunGard/Comdisco; the Antitrust Division's challenge to the sale by Tyson Foods of a poultry processing complex to George's Foods, and the City of New York's challenge to the combination of health insurers GHI and HIP to form Emblem Health.
Mike also has an active litigation practice and he has litigated and tried to a jury or a court a range of antitrust cases around the country involving claims of monopolization, anti-competitive agreements and unlawful acquisitions. This includes recent cases for Momenta Pharmaceuticals in a series of antitrust cases involving patent enforcement; Thales Group in dual patent litigations; Alvogen in a patent infringement and antitrust litigation regarding Indivior’s opioid dependency treatment drug Suboxone® Film and in the Generic Drugs MDL; and Tyson Foods in a putative antitrust class action litigation alleging a conspiracy to depress broiler grower pay.